QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NASDAQ:BLUE

bluebird bio (BLUE) Stock Forecast, Price & News

$3.03
-0.01 (-0.33%)
(As of 09/25/2023 ET)
Compare
Today's Range
$2.92
$3.10
50-Day Range
$3.03
$4.05
52-Week Range
$2.78
$8.58
Volume
3.12 million shs
Average Volume
4.23 million shs
Market Capitalization
$324.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.25

bluebird bio MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
139.1% Upside
$7.25 Price Target
Short Interest
Bearish
24.35% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.02mentions of bluebird bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$63,423 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.04) to ($2.00) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

681st out of 961 stocks

Biological Products, Except Diagnostic Industry

112th out of 161 stocks


BLUE stock logo

About bluebird bio (NASDAQ:BLUE) Stock

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

BLUE Price History

BLUE Stock News Headlines

Experts: "NVIDIA Bubble" Could Affect Entire Market
Several major analysts are warning that NVIDIA and other tech giants may have gotten “too big to succeed”.
Is Bluebird Bio a Bargain Buy in September?
Pentagon Consultant—Here's how Biden Wins Landslide Re-election
—but also hand Joe Biden a landslide re-election win. What would America look like if we slide further towards Socialism? Full story and 4 steps you can take,
Bluebird Bio (BLUE) Receives a Hold from RBC Capital
Barclays Releases a Buy Rating on Bluebird Bio (BLUE)
bluebird bio Q2 2023 Earnings Preview
EDIT Jul 2023 7.500 call
See More Headlines
Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

BLUE Company Calendar

Last Earnings
8/08/2023
Today
9/25/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLUE
Fax
N/A
Employees
323
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.25
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+139.1%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
10 Analysts

Profitability

Net Income
$-266,580,000.00
Net Margins
-1,020.37%
Pretax Margin
-1,019.98%

Debt

Sales & Book Value

Annual Sales
$3.60 million
Book Value
$2.37 per share

Miscellaneous

Free Float
104,707,000
Market Cap
$324.06 million
Optionable
Optionable
Beta
0.89

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Andrew  ObenshainMr. Andrew Obenshain (Age 49)
    Pres, CEO & Director
    Comp: $1.04M
  • Mr. Thomas J. Klima (Age 51)
    Chief Commercial Officer & COO
    Comp: $654.97k
  • Mr. Richard A. Colvin M.D. (Age 57)
    Ph.D., Chief Medical Officer
    Comp: $696.24k
  • Mr. Christopher Krawtschuk CPA (Age 49)
    CFO, Principal Accounting Officer & Treasurer
  • Mr. Joseph D. Vittiglio Esq. (Age 51)
    J.D., Chief Legal & Bus. Officer and Sec.
  • Jess Rowlands
    Head of Corp. Communications
  • Ms. Andrea Walton
    Chief People Officer
  • Mr. Kasra Kasraian
    Sr. VP of Technical Devel. & Operations
  • Mr. Scott Shoemaker
    Sr. VP of Quality
  • Ms. Sarah Alspach
    Sr. VP of External Affairs













BLUE Stock - Frequently Asked Questions

Should I buy or sell bluebird bio stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings
or view top-rated stocks.

What is bluebird bio's stock price forecast for 2023?

10 Wall Street research analysts have issued 12 month target prices for bluebird bio's shares. Their BLUE share price forecasts range from $3.00 to $10.00. On average, they anticipate the company's stock price to reach $7.25 in the next twelve months. This suggests a possible upside of 139.1% from the stock's current price.
View analysts price targets for BLUE
or view top-rated stocks among Wall Street analysts.

How have BLUE shares performed in 2023?

bluebird bio's stock was trading at $6.92 at the beginning of 2023. Since then, BLUE shares have decreased by 56.2% and is now trading at $3.03.
View the best growth stocks for 2023 here
.

When is bluebird bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our BLUE earnings forecast
.

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) issued its earnings results on Tuesday, August, 8th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.72) by $0.05. The biotechnology company had revenue of $6.90 million for the quarter, compared to the consensus estimate of $11.30 million. bluebird bio had a negative trailing twelve-month return on equity of 37.89% and a negative net margin of 1,020.37%. The company's revenue was up 360.0% compared to the same quarter last year. During the same period last year, the business earned ($1.29) EPS.

What ETFs hold bluebird bio's stock?
What is Nick Leschly's approval rating as bluebird bio's CEO?

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by many different institutional and retail investors. Top institutional investors include State Street Corp (15.30%), BlackRock Inc. (8.22%), Granahan Investment Management LLC (4.54%), Geode Capital Management LLC (2.08%), Credit Suisse AG (1.73%) and Dimensional Fund Advisors LP (1.30%). Insiders that own company stock include Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, David Davidson, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Nick Leschly, Richard A Colvin, Thomas J Klima and William D Baird III.
View institutional ownership trends
.

How do I buy shares of bluebird bio?

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $3.03.

How much money does bluebird bio make?

bluebird bio (NASDAQ:BLUE) has a market capitalization of $324.06 million and generates $3.60 million in revenue each year. The biotechnology company earns $-266,580,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.

How many employees does bluebird bio have?

The company employs 323 workers across the globe.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.bluebirdbio.com. The biotechnology company can be reached via phone at (339) 499-9300 or via email at investor@bluebirdbio.com.

This page (NASDAQ:BLUE) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -